Fresenius-licensed Endexo Smart Polymer Gets FDA Breakthrough Status to Prevent Clots
nterface Biologics Inc. (IBI) from Canada has developed Endexo as a way to help make dialyzer membranes and bloodlines more biocompatible—and less likely to clot. The technology, for which Fresenius holds an exclusive world-wide license, will reduce the need for heparin and other blood thinners.
Read the full article » | Posted 11/16/2019
Related Articles
- Start-ups Around the Globe Focus on Portable PD Posted 02/19/2020
- A Cure for What Ails Kidneys? Posted 02/19/2020
- BioIntelliSense BioSticker is FDA-approved Posted 02/19/2020
- AWAK PD Attracts Funding Posted 01/09/2020
- Portable, Wearable Dialysis—from Russia With Love Posted 12/10/2019